Ai Xiaojuan, Guo Xialing, Wang Jun, Stancu Andreea L, Joslin Patrick M N, Zhang Dianzheng, Zhu Shudong
National Key Discipline of Genetics, School of Life Sciences, Central South University, Changsha, China.
Argus Pharmaceuticals, Changsha, China.
Oncotarget. 2018 Dec 25;9(101):37589-37607. doi: 10.18632/oncotarget.26428.
Lung cancer is a serious health problem and the leading cause of cancer death worldwide, due to its high incidence and mortality. 85% of lung cancers are represented by the non-small cell lung cancer (NSCLC). Traditional chemotherapy has been the main treatment option in NSCLC. However, it is often associated with limited efficacy and overall poor patient survival. In recent years, molecular targeting has achieved great progress in therapeutic treatment of cancer and plays a crucial role in the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and reduced toxicity for normal tissues. In this review, we summarize the current targeting treatment of NSCLC, including inhibition of the epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3Ks), mechanistic target of rapamycin (mTOR), epidermal growth factor receptor 2 (ErbB2), vascular epidermal growth factor receptor (VEGFR), kirsten human rat sarcoma protein (KRAS), mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma viral oncogene homolog B (BRAF). This article may serve as a guide to clinicians and researchers alike by assisting in making therapeutic decisions. Challenges of acquired drug resistance targeted therapy and imminent newer treatment modalities against NSCLC are also discussed.
肺癌是一个严重的健康问题，也是全球癌症死亡的主要原因，这是由于其高发病率和死亡率所致。85%的肺癌为非小细胞肺癌（NSCLC）。传统化疗一直是NSCLC的主要治疗选择。然而，它常常疗效有限，患者总体生存率较差。近年来，分子靶向治疗在癌症治疗方面取得了巨大进展，并且由于对癌组织疗效增强以及对正常组织毒性降低，在当前NSCLC临床治疗中发挥着关键作用。在本综述中，我们总结了NSCLC目前的靶向治疗方法，包括对表皮生长因子受体（EGFR）、磷脂酰肌醇3激酶（PI3Ks）、雷帕霉素靶蛋白（mTOR）、表皮生长因子受体2（ErbB2）、血管内皮生长因子受体（VEGFR）、 Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）、间充质上皮转化因子或肝细胞生长因子受体（c-MET）、间变性淋巴瘤激酶（ALK）、v-Raf鼠肉瘤病毒癌基因同源物B（BRAF）的抑制作用。本文可通过协助做出治疗决策，为临床医生和研究人员提供指导。还讨论了获得性耐药靶向治疗的挑战以及针对NSCLC的即将出现的更新治疗模式。
